Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors

Reuters

Dec 11

Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors

Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate $(ADC)$, in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-$(L)$1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43154) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2590292518"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590292518\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590292518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590292518","market":"nz","top_or_hot":-1,"title":"Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-<a href=\"https://laohu8.com/S/L\">$(L)$</a>1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43154) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-<a href=\"https://laohu8.com/S/L\">$(L)$</a>1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43154) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3WQklh:1","article_id":"2590292518","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590292518","pubTimestamp":1765454559,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate , in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology  Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer , 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"Biohaven报告BHV-1510联合Cemiplimab治疗晚期实体瘤的有希望的1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors\n    \n\n        Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate $(ADC)$, in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-$(L)$1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43154) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}